Sep 16, 2019 8:00am EDT Benitec Biopharma Provides Update on BB-301 Oculopharyngeal Muscular Dystrophy (OPMD) Program
Sep 19, 2018 8:00am EDT Benitec Biopharma Announces the Appointment of Gregory R. Reyes, M.D., Ph.D. as Senior Scientific Advisor
Jul 08, 2018 8:59pm EDT Benitec Announces Global Licensing Agreement for BB-301 for Treatment of Oculopharyngeal Muscular Dystrophy and Broad Platform Collaboration with Axovant
May 31, 2018 8:00am EDT Benitec Biopharma reports financial results for the 2018 fiscal third quarter and provides operational update
May 15, 2018 8:00am EDT Benitec to present OPMD data at the American Society of Gene and Cell Therapy Meeting
May 03, 2018 8:00am EDT Benitec to Host Investor Webinar on the Company's Oculopharyngeal Muscular Dystrophy (OPMD) Program
